In this enlightening discussion, Joseph Mikhael, a myeloma expert from TGen and the International Myeloma Foundation, tackles the pressing issues in myeloma treatment. He highlights breakthroughs in managing smoldering myeloma and the unique challenges faced by frail and elderly patients. The conversation also dives into innovative therapies for triple-class refractory disease, and the critical examination of racial disparities in myeloma care. Mikhael’s insights showcase the need for improved access and personalized treatment approaches.

Lalit Kumar, an expert in blood cancer management from Artemis Hospital in India, discusses the challenges of diagnosis and treatment in rural areas. Joseph Mikhael, from the Translational Genomics Research Institute, highlights racial disparities in multiple myeloma treatment in the U.S., emphasizing the need for education and trust. Other guests address socioeconomic barriers in clinical trial recruitment and the stark differences in care accessibility for chronic lymphocytic leukemia across various income countries, advocating for more equitable healthcare options.

Dr Joseph Mikhael discusses updates in multiple myeloma management, including the concept of stopping treatment for patients with deep responses, the use of MRD negativity to determine treatment level, neurological toxicities associated with certain treatments, utilization of specific treatments in medical oncology offices, advantages of bertimide vs. lintalitamide, and the examination of a treatment for multiple myeloma.